Affinity Asset Advisors’s Pulmonx LUNG Stock Holding History

Affinity Asset Advisors’s Portfolio LUNG Stock Details LUNG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-25,000	Closed	-$900K	–	66
2021 Q3	$900K	Sell	25,000 -35,000	-58%	-$1.38M	0.23%	60
2021 Q2	$2.65M	Buy	60,000 +15,000	+33%	+$653K	0.95%	26
2021 Q1	$2.06M	Buy	45,000 +25,000	+125%	+$1.43M	0.7%	36
2020 Q4	$1.38M	Buy	+20,000	New	+$979K	0.73%	35

Other funds holding LUNG

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

MGM

Miura Global Management New York $25.2M AUM 60.6% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Affinity Asset Advisors's LUNG Position: Q4 2021 in Review

Affinity Asset Advisors sold out of Pulmonx (LUNG) in Q4 2021, closing a stake of 25,000 shares — an estimated $900K sold.

Affinity Asset Advisors first reported a position in LUNG in Q4 2020 and held it in 4 quarters. The position peaked at $2.65M in Q2 2021. 114 funds tracked by Wall St. Rank hold LUNG as of Q4 2021.

Affinity Asset Advisors reported no remaining Pulmonx position as of Q4 2021 after selling out during the quarter.
Affinity Asset Advisors sold 25,000 Pulmonx shares in Q4 2021, an estimated $900K.
Affinity Asset Advisors first reported a position in Pulmonx in Q4 2020 and held it in 4 quarters.
Affinity Asset Advisors's Pulmonx position peaked at $2.65M in Q2 2021.
114 funds tracked by Wall St. Rank held Pulmonx as of Q4 2021.

Based on Affinity Asset Advisors's 13F filing for Q4 2021, filed 11 Feb 2022.